Search­ing for the next 'big hairy goal,' Blue­Rock CEO Emile Nuwaysir jumps to in vi­vo cell ther­a­py start­up En­so­ma

Two years af­ter Bay­er swal­lowed the re­main­ing shares of his re­gen­er­a­tive cell ther­a­py com­pa­ny, Emile Nuwaysir has found him­self a new “big hairy goal”: in vi­vo cell ther­a­py.

En­so­ma, an am­bi­tious and well-backed start­up out of Fred Hutch and the Uni­ver­si­ty of Wash­ing­ton, has tapped Nuwaysir as the new CEO. It’ll be the se­r­i­al ex­ec­u­tive’s sec­ond stint as a CEO af­ter Blue­Rock, where he shep­herd­ed a first-of-its-kind cell ther­a­py for Parkin­son’s dis­ease in­to clin­i­cal tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER